Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study
- 25 February 2005
- journal article
- clinical trial
- Published by Wiley in Movement Disorders
- Vol. 20 (7), 783-791
- https://doi.org/10.1002/mds.20403
Abstract
Botulinum toxin type A (Dysport) has been shown in European studies to be a safe and effective treatment for cervical dystonia. This multicenter, double‐blind, randomized, controlled trial assessed the safety and efficacy of Dysport in cervical dystonia patients in the United States. Eighty patients were randomly assigned to receive one treatment with Dysport (500 units) or placebo. Participants were followed up for 4 to 20 weeks, until they needed further treatment. They were assessed at baseline and weeks 2, 4, 8, 12, 16, and 20 after treatment. Dysport was significantly more efficacious than placebo at weeks 4, 8, and 12 as assessed by the Toronto Western Spasmodic Torticollis Rating Scale (10‐point vs. 3.8‐point reduction in total score, respectively, at week 4; P ≤ 0.013). Of participants in the Dysport group, 38% showed positive treatment response, compared to 16% in the placebo group (95% confidence interval, 0.02–0.41). The median duration of response to Dysport was 18.5 weeks. Side effects were generally similar in the two treatment groups; only blurred vision and weakness occurred significantly more often with Dysport. No participants in the Dysport group converted from negative to positive antibodies after treatment. These results confirm previous reports that Dysport (500 units) is safe, effective, and well‐tolerated in patients with cervical dystonia. © 2005 Movement Disorder SocietyKeywords
This publication has 14 references indexed in Scilit:
- Altered Discharge Pattern of Basal Ganglia Output Neurons in an Animal Model of Idiopathic DystoniaJournal of Neuroscience, 2002
- Efficacy and safety of a standardised 500 unit dose of Dysport ® (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group studyZeitschrift für Neurologie, 2001
- The Neurophysiology of DystoniaArchives of Neurology, 1998
- What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using DysportJournal of Neurology, Neurosurgery & Psychiatry, 1998
- A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystoniaJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystoniaNeurology, 1997
- Botulinum toxin versus trihexyphenidyl in cervical dystoniaNeurology, 1996
- A double blind trial of botulinum toxin "A" in torticollis, with one year follow up.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Botulinum toxin treatment in spasmodic torticollis.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Epidemiology of focal and generalized dystonia in Rochester, MinnesotaMovement Disorders, 1988